Four Danish patients who experienced vision loss after using Novo Nordisk's Wegovy and Ozempic were awarded compensation ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk’s popular weight-loss and diabetes drugs ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against companies selling versions ...

Low doses of these popular drugs can reverse ageing, scientists say - Researchers say findings provide evidence for ...

It's now just five weeks until Christmas - the season which, for most of us, means a hefty dose of over-indulgence.

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for ...

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access ...

That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that ...